Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 12;4(1):21-37.
doi: 10.3233/ADR-190143.

Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease

Shahul Hameed  1   2 , Jong-Ling Fuh  3   4 , Vorapun Senanarong  5 , Esther Gunaseli M Ebenezer  6 , Irene Looi  7   8 , Jacqueline C Dominguez  9 , Kyung Won Park  10 , Ananda Krishna Karanam  11 , Oliver Simon  12
Affiliations
Review

Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease

Shahul Hameed et al. J Alzheimers Dis Rep. .

Abstract

Clinical diagnosis of Alzheimer's disease (AD) is based on symptoms; however, the challenge is to diagnose AD at the preclinical stage with the application of biomarkers and initiate early treatment (still not widely available). Currently, cerebrospinal fluid (CSF) amyloid-β 42 (Aβ42) and tau are used in the clinical diagnosis of AD; nevertheless, blood biomarkers (Aβ42 and tau) are less predictive. Amyloid-positron emission tomography (PET) imaging is an advancement in technology that uses approved radioactive diagnostic agents (florbetapir, flutemetamol, or florbetaben) to estimate Aβ neuritic plaque density in adults with cognitive impairment evaluated for AD and other causes of cognitive decline. There is no cure for AD to date-the disease progression cannot be stopped or reversed; approved pharmacological agents (donepezil, galantamine, and rivastigmine; memantine) provide symptomatic treatment. However, the disease-modifying therapies are promising; aducanumab and CAD106 are in phase III trials for the early stages of AD. In conclusion, core CSF biomarkers reflect pathophysiology of AD in the early and late stages; the application of approved radiotracers have potential in amyloid-PET brain imaging to detect early AD.

Keywords: Alzheimer’s disease; biomarker; blood; cerebrospinal fluid; early diagnosis; positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

Oliver Simon and Ananda Krishna Karanam are employees of Novartis. The remaining authors have nothing to disclose.

References

    1. Gale SA, Acar D, Daffner KR (2018) Dementia. Am J Med 131, 1161–1169. - PubMed
    1. Scott KR, Barrett AM (2007) Dementia syndromes: Evaluation and treatment. Expert Rev Neurother 7, 407–422. - PMC - PubMed
    1. Prizer LP, Zimmerman S (2018) Progressive support for activities of daily living for persons living with dementia. Gerontologist 58, S74–87. - PMC - PubMed
    1. Jing W, Willis R, Feng Z (2016) Factors influencing quality of life of elderly people with dementia and care implications: A systematic review. Arch Gerontol Geriatr 66, 23–41. - PubMed
    1. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M (2015) World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends Alzheimer’s Disease International, London. http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. Accessed January 8, 2020.

LinkOut - more resources